Entity

Time filter

Source Type


Rodriguez-Moran M.,Mexican Social Security Institute | Rodriguez-Moran M.,The Research Group on Diabetes and Chronic Illnesses | Guerrero-Romero F.,Mexican Social Security Institute | Guerrero-Romero F.,The Research Group on Diabetes and Chronic Illnesses
Diabetes/Metabolism Research and Reviews | Year: 2011

Background: Magnesium modulates insulin-mediated glucose uptake but data regarding its role in insulin secretion are scarce; therefore, in this study we determined whether decreased serum magnesium levels are associated with the impairment of insulin secretion in non-diabetic individuals. Methods: A total of 182 apparently healthy subjects, men and non-pregnant women, 18-65 years of age, were enrolled in a population-based cross-sectional study and allocated to groups with hypomagnesaemia and normomagnesaemia. The groups in the study were subsequently stratified according to glucose status: normal glucose tolerance, impaired fasting glucose, and impaired glucose tolerance. Insulin secretion was evaluated by the first and second phases of insulin secretion. Results: The Spearman coefficient between serum magnesium and the first and second phases of insulin secretion showed a significant positive correlation in the overall (r = 0.265, p < 0.0005; r = 0.541, p < 0.0005), normal glucose tolerance (r = 0.369, p = 0.001; r = 0.618, p < 0.0005), impaired fasting glucose (r = 0.320, p = 0.02; r = 0.449, p = 0.001), and impaired glucose tolerance (r = 0.129, p = 0.37; r = 0.522, p < 0.0005) groups. The multivariate linear regression analysis showed a significant association between serum magnesium levels and the first and second phases of insulin secretion: for the entire groups [B = 75.2; 95% confidence interval (CI) 27.6-122.7; B = 25.4; 95% CI 16.4-34.3], normal glucose tolerance (B = 129.6, 95% CI 38.1-221.1; B = 40.3, 95% CI 23.7-56.8), impaired fasting glucose (B = 75.2, 95% CI 27.6-122.7; B = 15.1, 95% CI 4.2-30.2), and impaired glucose tolerance (B = 57.4, 95% CI 23.5-138.3; B = 25.4, 95% CI 16.4-34.3) groups. Conclusions: Our results show that hypomagnesaemia is associated with the decrease of the first and second phases of insulin secretion in non-diabetic subjects with hypomagnesaemia. © 2011 John Wiley & Sons, Ltd.


Guerrero-Romero F.,Mexican Social Security Institute | Guerrero-Romero F.,The Research Group on Diabetes and Chronic Illnesses | Rodriguez-Moran M.,Mexican Social Security Institute | Rodriguez-Moran M.,The Research Group on Diabetes and Chronic Illnesses
European Journal of Clinical Investigation | Year: 2011

Background: Given that role of magnesium in insulin secretion is uncertain, our objective was to determine whether oral supplementation with magnesium chloride (MgCl 2) improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia. Materials and methods Eligible individuals were non-diabetic, normo-tensive men and non-diabetic, normo-tensive, non-pregnant women with serum magnesium levels ≤0·70mM/L; they were enrolled in a randomized double-blind clinical trial to receive either 50mL of 5% MgCl 2 solution or 50mL of inactive solution daily for 3months. The primary trial end point was a change in the AUC of the hyperbolic model of beta-cell function (HMbCF) derived from the fasting state. Individuals, caregivers and personnel who assessed the outcomes were all blinded to the group assignments. Results A total of 54 and 52 individuals were assigned to the MgCl 2 and placebo groups, respectively; five individuals in the MgCl 2 group and four in the placebo group dropped out. There were no serious adverse events or side effects because of MgCl 2 or placebo. At the beginning of the study, the AUC of the HMbCF was similar in both groups (AUC=7·591 and 7·895cm 2); at the end of follow-up, the curve of the MgCl 2 group showed a hyperbolic distribution (AUC=18·855cm 2), whereas in the placebo group, there were no changes (AUC=7·631cm 2). Conclusions: MgCl 2 2·5g daily improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia. © 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Discover hidden collaborations